首页 / 院系成果 / 成果详情页

Comparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management 期刊论文

编号：

3DEBBB7507C52AC670A06D69D1EF9202
作者：

Sucupira, Maria Cecilia Araripe^[1];Schechter, Mauro^[1,2];Castelo Filho, Adauto^[1];Ferreira, Fernanda^[1];Inocencio, Lilian Amaral^[1];de Souza, Denise Ferreira^[1];Diaz, Ricardo Sobhie^[1]
语种：

英文
期刊：

AIDS RESEARCH AND HUMAN RETROVIRUSES ISSN：0889-2229 2024 年 ; 2024 OCT 28
疾病分类：

艾滋病
关键词：

HIV viral load assays HIV subtypes Brazil
摘要：

HIV RNA plasma viral load (VL) is the standard surrogate marker to monitor response to antiretroviral treatment (ART). We compared the linearity, repeatability, and concordance of six commercially available HIV RNA VL platforms using clinical samples from patients from Brazilian sites where different HIV-1 subtypes co-circulate. A total of 150 plasma samples from each city were collected in Curitiba, Southern Brazil (subtype C), S & atilde;o Paulo (subtype B), and Santos (BF recombinants), Southeast Brazil. Platforms were VERSANT (R) Siemens HIV RNA 1.0 (kPCR); VERSANT (R) Siemens HIV-1 RNA 3.0 (bDNA); Abbott Real-Time HIV-1; NucliSens EasyQ (R) HIV-1 v2.0 Biomerieux; COBAS (R) TaqMan (R), Roche; and artus HIV Virus-1 RT-PCR, QIAGEN. OptiQuant HIV-1 RNA quantification panel was used to compare VL linearity, using samples containing 50, 500,5,000, 50,000, 500,000, and 5,000,000 HIV copies/mL. HIV RNA panels with subtypes A, B, C, D, F, G, H, circulating recombinant form (CRF)1, and CRF2 were utilized. A high degree of linearity and repeatability was demonstrated for all platforms. When compared with a subtype B reference sample, 17 of 54 (31.48%) samples diverged by more than 0.5 log10 copies/mL. Except for the Roche platform, all platforms underestimated subtype C VLs. A total of 743 (82.6%) valid results were obtained with samples from S & atilde;o Paulo, 707 (78.6%) from Santos, and 673 (74.8%) from Curitiba (S & atilde;o Paulo vs. Santos, p = .03; S & atilde;o Paulo vs. Curitiba, p = .00006; Santos vs. Curitiba, p = .06). The number of discordant samples between different methodologies when VL was undetectable in one method and detectable in the other ranged from 1.25% (Abbot vs. Siemens) to 44.8% (Abbott vs. Biomerieux). Finding samples with undetectable VL in one method and a high VL in another might have important individual and public health consequences. Standardization of VL measurements, particularly for non-B subtypes infections, especially subtype C, is necessary to maximize the individual and public health benefits of ART globally.
推荐引用方式
GB/T 7714：

Sucupira Maria Cecilia Araripe,Schechter Mauro,Castelo Filho Adauto, et al. Comparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management [J].AIDS RESEARCH AND HUMAN RETROVIRUSES,2024.
APA：

Sucupira Maria Cecilia Araripe,Schechter Mauro,Castelo Filho Adauto,Ferreira Fernanda,&Diaz Ricardo Sobhie.(2024).Comparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management .AIDS RESEARCH AND HUMAN RETROVIRUSES.
MLA：

Sucupira Maria Cecilia Araripe, et al. "Comparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management" .AIDS RESEARCH AND HUMAN RETROVIRUSES(2024).
数据来源自科睿唯安Web of Science核心合集
入库时间：

2024/12/9 14:29:27
更新时间：

2024/12/9 14:29:27

浏览次数：6  下载次数：0

分享到：

浏览次数：6

下载次数：0

打印次数：0